All In Biotech

Drug Trial Radar · NCT01578278

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

Last checked: Nov 20, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 606 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

606

Actual

Start

Dec 2011

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Apr 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a clinical study to evaluate the safety and efficacy of a bepotastine besilate-corticosteroid combination nasal spray for the treatment of seasonal allergic rhinitis (SAR) in an open exposure study with subjects who have a demonstrated history of Mountain Cedar pollen allergy. The primary study objective is to assess the reduction from baseline in averaged morning (AM) and evening (PM) values of reflective total nasal symptom scores for each of 3 nasal sprays (bepotastine besilate-fluticasone propionate combination nasal spray, bepotastine besilate nasal spray, fluticasone propionate nasal spray) compared to placebo nasal spray. For enrolled subjects, the study will involve a 7-10 day run-in screening period dosing with placebo nasal spray and then a 14-day treatment period where subjects will dose twice a day with 1 of the 4 test agent nasal sprays and record reflective and instantaneous scores for both nasal and ocular symptoms prior to each dosing.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • Bepotastine besilate formulationDrug

    Nasal Spray

  • Fluticasone propionateDrug

    Nasal Spray

  • Bepotastine besilate-fluticasone propionateDrug

    Nasal Spray

  • Placebo ComparatorDrug

    Nasal Spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline (Pre-Dose) in Morning and Evening Averaged Subject-rated Reflective TNSSTime frame: Baseline, 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ISTA Pharmaceuticals, Inc.

    Irvine, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.